# Eisai

Source: https://onco.cc/companies/eisai/  
OnCo record `eisai` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Japanese pharma that makes lenvatinib (Lenvima), a first-line option in liver cancer and a partner of pembrolizumab in several tumours.

## Summary

Eisai is the Tokyo-based pharmaceutical company, listed as 4523.T, that makes lenvatinib, sold as Lenvima, a first-line option in liver cancer and a partner of pembrolizumab in several tumours. Lenvatinib is approved in hepatocellular carcinoma on the REFLECT trial, in thyroid cancer, in renal cell carcinoma with everolimus or pembrolizumab, and in endometrial cancer with pembrolizumab, and Eisai co-develops the LEAP programme of lenvatinib plus pembrolizumab with Merck, in which LEAP-002 in first-line liver cancer and LEAP-012 with TACE both missed their overall survival endpoints. OnCo also links it to eribulin, palonosetron and denileukin diftitox, and to salivary gland cancers and thymic tumours. Whether the LEAP combination has further indications left after two negative liver trials is the open question. Lenvatinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Tokyo
- Type: pharma
- Website: https://www.eisai.com
- Ticker: 4523.T

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Eisai_(company)
- Official website: https://www.eisai.com

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Alitretinoin](https://onco.cc/drugs/alitretinoin/), [Denileukin diftitox](https://onco.cc/drugs/denileukin-diftitox/), [Eribulin](https://onco.cc/drugs/eribulin/), [Farletuzumab ecteribulin](https://onco.cc/drugs/farletuzumab-ecteribulin/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Palonosetron](https://onco.cc/drugs/palonosetron/), [Pilocarpine](https://onco.cc/drugs/pilocarpine/)
- trials: [A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor](https://onco.cc/trials/nct04008797/), [A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor](https://onco.cc/trials/nct04078295/), [A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study](https://onco.cc/trials/nct05899049/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types](https://onco.cc/trials/nct04300556/), [CLEAR (KEYNOTE-581)](https://onco.cc/trials/clear/), [KEYNOTE-775 / Study 309](https://onco.cc/trials/keynote-775/), [LEAP-002](https://onco.cc/trials/leap-002/), [LEAP-012](https://onco.cc/trials/leap-012/), [LITESPARK-011](https://onco.cc/trials/nct04586231/), [REFLECT](https://onco.cc/trials/reflect/), [SELECT](https://onco.cc/trials/select-lenvatinib/), [Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma](https://onco.cc/trials/nct01127451/)
- companies: [Citius Pharmaceuticals](https://onco.cc/companies/citius-pharmaceuticals/)
- key papers: [Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial](https://onco.cc/key-papers/paper-litespark-011-motzer-lancet-2026/)

---
JSON: https://onco.cc/api/v1/entities/eisai.json